Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Rated as 'Moderate Buy' by Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has recently received an average rating of "Moderate Buy" from five research firms analyzing the company's stock, according to reports from MarketBeat Ratings. Out of these analysts, two have assigned a hold rating, while the other three have suggested buying the stock. The analysts have set an average target price of $38.00 for the company over the next year.

Several research reports have been published regarding Inovio Pharmaceuticals. On November 15th, Royal Bank of Canada announced a decrease in their price target for the stock from $7.00 to $6.00, while maintaining a "sector perform" rating. On November 18th, HC Wainwright also reduced their price target from $12.00 to $5.00 and classified the company with a "neutral" rating. Furthermore, Oppenheimer revised their target from $33.00 to $15.00 on the same day, rating the company as "outperform".

Inovio Pharmaceuticals Stock Overview

As of Thursday, INO stock opened at $4.03. Over the past year, Inovio Pharmaceuticals has seen its stock price reach a low of $3.85 and a high of $14.75. Presently, the company has a market capitalization of approximately $105.05 million, a price-to-earnings ratio standing at -1.16, and a beta value of 0.75. The stock's fifty-day moving average is priced at $4.99, while its two-hundred-day moving average stands at $7.23.

Recent Institutional Activity

Institutional investors have been active regarding Inovio Pharmaceuticals recently, either increasing or decreasing their stakes in the company. Barclays PLC significantly raised its stake by 282.6% in the third quarter, acquiring an additional 25,116 shares to total 34,003 shares valued at $197,000. Geode Capital Management LLC grew its holdings by 6.7%, now owning 621,631 shares worth $3,594,000 after acquiring 38,833 shares in the same quarter. Also in the third quarter, Wellington Management Group LLP entered a new position with shares valued at roughly $379,000. State Street Corp enhanced its holdings by 11.7%, ending up with 490,662 shares valued at approximately $2,836,000 after purchasing 51,414 shares. Atom Investors LP also established a new stake valued at around $103,000 during the same period. Institutional investors collectively own about 26.79% of Inovio's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines intended to treat and prevent diseases like human papillomavirus (HPV), various cancers, and additional infectious diseases. Utilizing its DNA medicines platform, Inovio employs precisely designed SynCon technology to identify and optimize DNA sequences targeting specific antigens, along with CELLECTRA smart devices designed to efficiently deliver the DNA plasmids.

Conclusion

Overall, Inovio Pharmaceuticals continues to attract interest from analysts and institutional investors alike. With various target price adjustments noted, market participants are closely monitoring the company's performance and prospects going forward.

Inovio, Pharmaceuticals, Stocks